Epothilone Analogs by Genetic Engineering

Information

  • Research Project
  • 6403365
  • ApplicationId
    6403365
  • Core Project Number
    R43CA093100
  • Full Project Number
    1R43CA093100-01
  • Serial Number
    93100
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2001 - 23 years ago
  • Project End Date
    6/30/2002 - 22 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    7/1/2001 - 23 years ago
  • Budget End Date
    6/30/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/1/2001 - 23 years ago
Organizations

Epothilone Analogs by Genetic Engineering

DESCRIPTION (provided by applicant): The long term objective of this proposal is to generate novel anticancer agents which are commercially feasible to prepare by fermentation processes. Epothilone D, a 16-membered polyketide-derived macrolactone, has promising antitumor activity but is produced in low titers by the native organism, Sorangium cellulosum, and is only sparingly soluble in water. Chemical synthesis of epothilones has been achieved but the methods are elaborate and not feasible for scale-up for pharmaceutical applications. The Phase I Specific Aim of this proposal is to generate a number of epothilone analogs by genetic engineering which are more water soluble than and at least as potent as the parent. These analogs will be tested in cell culture (taxol susceptible and resistant lines) and in vitro assays and water solubility measured (octanol-water partition coefficients). Phase II would involve the generation of additional analogs by diketide feeding. The two best compounds in terms of a) potency, b) water solubility and c) economics of production would be carried forward into further testing. Sufficient amounts of each would be produced to use in animal tumor models and in preliminary animal toxicity and pharmacokinetic studies. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    KOSAN BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    932981319
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94545
  • Organization District
    UNITED STATES